Professor
University of British Columbia
Kelowna, British Columbia
Zach Walsh, PhD, is a clinical psychologist, a Research Affiliate with the BC Centre on Substance Use, and a Professor of Psychology at the University of British Columbia, where he directs the Therapeutic, Recreational, and Problematic Substance Use lab and the Problematic Substance Use clinic.
Zach is a member of the Advisory Board of MAPS Canada and a member of the International Research Society on Psychedelics. He has published and presented widely on topics related to psychedelics, cannabis, mental health and psychotherapy, was a member of the clinical team for the Phase 2 MAPS sponsored study of MDMA-assisted psychotherapy for PTSD, and for an ongoing clinical trial of psilocybin-assisted psychotherapy for Alcohol Use Disorder. Zach led the first Canadian clinical trial of cannabis for PTSD and currently leads a trial of psilocybin-assisted psychotherapy for opioid titration in chronic pain. Zach also leads microdose.me, which is a large international observational trial of microdosing, as well as several ongoing studies of ketamine, cannabis and kratom. Zach’s clinical interests include psychedelic psychotherapy training and the integration of “third wave” mindfulness-based behavior therapies with psychedelic-assisted psychotherapy.
E15 - Use of Ketamine in Treatment of Behavioral Health Conditions
Wednesday, April 17, 2024
10:30 AM – 11:30 AM CT